Neoantigen Cancer Vaccines: The Rise of Truly Personalized Immunotherapy—And the Execution Gap That Will Define Winners

Neoantigen cancer vaccines are moving from a compelling concept to a pragmatic therapeutic strategy because they exploit what makes each tumor distinct: its mutation-derived antigens. By sequencing a patient’s tumor and normal tissue, teams can identify tumor-specific neoantigens, predict which peptides are most likely to be presented on that patient’s HLA molecules, and manufacture a personalized vaccine designed to train T cells to recognize and destroy malignant cells while sparing healthy tissue.

What is trending now is not just personalization, but operationalization. The field is converging on faster end-to-end pipelines, more accurate epitope prediction models, and manufacturing approaches that can meet clinical timelines. Equally important, developers are treating the vaccine as one component of a broader immune strategy, pairing it with checkpoint inhibitors or other immune modulators to overcome tumor immune evasion and expand the depth and durability of responses. This shift reframes the vaccine from a standalone product into an immune “software update” that can be iterated as the tumor evolves.

For decision-makers, the key questions are becoming clearer: Can you consistently deliver high-quality personalized product within a clinically meaningful turnaround time? How will you manage HLA diversity, tumor heterogeneity, and antigen loss? And how will you prove value with endpoints that capture long-term benefit, not just short-term tumor shrinkage? The winners will combine strong biology with disciplined execution across data, manufacturing, and clinical design, turning individualized vaccines into scalable, repeatable care pathways.